Setmelanotide: the peptide for genetic obesity and how MC4R works

How the MC4R pathway controls hunger

The brain's hypothalamus runs a hunger-control circuit that relies on a chain of signals. Fat tissue releases leptin, which acts on its receptor (LEPR) in the hypothalamus; that drives production of a precursor protein, POMC, which is cut by an enzyme, PCSK1, into alpha-MSH; and alpha-MSH activates the melanocortin 4 receptor (MC4R), which reduces hunger and raises energy use. A 2018 analysis describes the MC4R pathway as serving a critical role in body weight, with loss-of-function mutations in POMC, PCSK1, LEPR or MC4R causing early-onset severe obesity (genetic study) ¹.

When any link breaks, the signal does not reach MC4R, and hunger can be relentless from early childhood. The same analysis estimated more than 12,800 people in the United States with two faulty copies of POMC, PCSK1 or LEPR, few of them genetically diagnosed (epidemiological estimate) ¹.

What setmelanotide does

Setmelanotide is a synthetic peptide that activates MC4R directly, bypassing the broken upstream links. Its label describes it as an MC4 receptor agonist with 20-fold less activity at the MC3 and MC1 receptors, and says it may re-establish MC4 receptor pathway activity, reducing food intake and promoting weight loss through lower calorie intake and higher energy expenditure in people whose obesity is associated with insufficient MC4R activation (drug label) ². It is injected under the skin once daily; its half-life is about 11 hours ².

The melanocortin receptors are a family, and the others matter for side effects and design. MC1R sits on pigment cells, which is why darkening occurs ². MC3R is also involved in energy balance, though a 2026 cross-species study implicated it more strongly in the control of puberty than in body weight (genetic and animal study) ³. Setmelanotide's relative selectivity for MC4R over MC3R and MC1R ² is what distinguishes it from unselective agonists such as melanotan II, which act broadly across the family ⁴.

Who the label covers, as of October 3, 2026

The current Imcivree label covers reducing excess weight and maintaining the reduction in people aged 4 and over with acquired hypothalamic obesity, obesity caused by damage to the hypothalamus, and in people aged 2 and over with Bardet-Biedl syndrome or with POMC, PCSK1 or LEPR deficiency confirmed by genetic testing (drug label) ². The label is explicit about what it does not cover: obesity with gene variants classed as benign, and other types of obesity, including other genetic syndromes and general (polygenic) obesity, in which it would not be expected to work ².

That narrowness is the point. Setmelanotide restores a missing signal; in most people with obesity the signal is not missing, so there is nothing to restore.

What the trials found

The trials are small, because the conditions are rare, but the effects in the right patients are large. In open-label phase 3 trials, after about a year 8 of 10 people with POMC deficiency and 5 of 11 with LEPR deficiency lost at least 10% of body weight, with hunger scores down 27% and 44%; injection-site reactions affected everyone (open-label trials) ⁵. In Bardet-Biedl syndrome, 32.3% of patients aged 12 and over lost at least 10% after 14 placebo-controlled weeks and 52 weeks of treatment, while results in Alström syndrome were inconclusive (phase 3 trial) ⁶.

In acquired hypothalamic obesity, an open phase 2 trial found 16 of 18 people reached at least a 5% fall in BMI, averaging 15% (open-label trial) ⁷, and a 2026 randomised phase 3 trial in people aged 4 to 66 found BMI changed by -16.5% against +3.3% on placebo over 52 weeks, with hunger falling more; serious adverse events occurred in 28% against 8% (randomised trial) ⁸. In children aged 2 to 5, BMI fell 18% on average at 52 weeks (open-label phase 3) ⁹.

Skin darkening: the melanotan connection

Setmelanotide's best-known side effect follows from its chemistry. The label explains that the MC1 receptor is expressed on melanocytes, the skin's pigment cells, and that activating it causes melanin to build up and skin to darken independently of sunlight; it warns of generalised skin darkening, darkening of existing moles and new moles, and advises a full skin examination before starting and periodically during treatment (drug label) ². Skin darkening affected 61% of patients in the Bardet-Biedl trial ⁶.

The same receptor family is why melanotan II, an unselective melanocortin agonist sold online for tanning, darkens skin ⁴, and why PT-141 (Vyleesi) carries a warning about focal skin darkening ¹⁰. Setmelanotide was designed to favour MC4R, with 20-fold less activity at MC1R ², yet it still darkens skin in many patients, a measure of how sensitive pigment cells are to this receptor family. Our melanotan II and PT-141 page covers what happens when two such agonists are combined.

The other warnings

The label carries several more warnings. Spontaneous penile erections in males and sexual adverse reactions in females have occurred, and an erection lasting more than four hours needs emergency care. Depression and suicidal ideation have occurred, and patients should be monitored, with discontinuation considered if they arise. Serious hypersensitivity reactions, including anaphylaxis, have been reported. In acquired hypothalamic obesity, patients should be monitored for signs of acute adrenal insufficiency, and in those who also have central diabetes insipidus, for sodium imbalance: in the hypothalamic obesity trial, low sodium was reported in 6% on setmelanotide against 2% on placebo, so the label advises monitoring sodium when fluid intake or hydration changes (drug label) ². The most common reactions across indications include skin darkening, injection-site reactions, nausea, headache, diarrhoea, abdominal pain, vomiting, depression and spontaneous erection ².

Hunger and energy use, not just appetite

Setmelanotide does more than blunt appetite. In a short study described in its label, 12 otherwise healthy people with obesity had higher resting energy expenditure and burned proportionally more fat after short-term treatment; the label adds that its safety and effectiveness have not been established in such people and that it is not approved for them (drug label) ². In the target conditions, hunger itself falls: hunger scores dropped 27% and 44% in the POMC and LEPR trials ⁵, and hunger fell more than on placebo in the 2026 hypothalamic obesity trial ⁸. Hunger was measured directly in these trials, alongside weight, because it is central to these conditions.

Why people without these conditions should not use it

Because setmelanotide works in the brain and changes energy use, it can look like an attractive weight-loss tool. The label rules that out: in general obesity it would not be expected to work, and its safety and effectiveness have not been established there ². Meanwhile its warnings, from depression and suicidal thoughts to skin and mole changes and spontaneous erections ², apply to anyone who takes it. The balance that justifies those risks in a child with POMC deficiency does not exist for someone with ordinary obesity, for whom approved GLP-1 drugs have far broader evidence.

How it differs from GLP-1 drugs

Semaglutide and tirzepatide act on gut-hormone receptors and work across most people with obesity. Setmelanotide acts further down the brain's hunger pathway, at MC4R, and its label confines it to people whose pathway is broken or damaged ². The two classes are not substitutes for each other in either direction: a GLP-1 drug is not the targeted treatment for POMC deficiency, and setmelanotide is not expected to work for common obesity. Our semaglutide brands guide covers the GLP-1 side.

Genetic testing and diagnosis

Because the label depends on a specific diagnosis, genetic testing is central. For POMC, PCSK1 and LEPR deficiency, the label requires confirmation by genetic testing showing variants interpreted as pathogenic, likely pathogenic or of uncertain significance ². Clues that a doctor might consider testing include severe obesity starting in early childhood with intense hunger. The 2018 analysis suggests most people with these variants have never been diagnosed ¹.

Questions to ask a specialist

• Could my or my child's obesity have a genetic or hypothalamic cause, and is testing appropriate?
• If a variant is found, does it qualify under the label?
• How will skin and moles be monitored, and how often?
• What signs of depression or adrenal problems should we watch for?
• What results would show it is working, and when should we expect them?

The bottom line

Setmelanotide is a precision peptide: it replaces a missing hunger signal at MC4R for people with specific gene defects, Bardet-Biedl syndrome or hypothalamic injury, and in them it can produce large, sustained weight and hunger reductions. It is not for general obesity. Its skin darkening comes from the same receptor family as melanotan's, and its label asks for skin checks and watchfulness for mood changes. For the families it fits, it is one of the clearest successes in peptide medicine.

Frequently asked questions

What is setmelanotide?

An approved peptide, sold as Imcivree, that activates the MC4 receptor in the brain to reduce hunger in people with specific genetic or hypothalamic causes of obesity.

Who can take Imcivree?

Per its label: people aged 4 and over with acquired hypothalamic obesity, and people aged 2 and over with Bardet-Biedl syndrome or genetically confirmed POMC, PCSK1 or LEPR deficiency.

Does setmelanotide work for regular obesity?

No. Its label says it is not expected to be effective in general (polygenic) obesity or other genetic syndromes outside its indications.

Why does setmelanotide darken skin?

It also activates the MC1 receptor on pigment cells, which increases melanin. The label advises skin examinations before and during treatment because moles can darken or new ones appear.

How much weight do people lose on setmelanotide?

In a 2026 randomised trial in hypothalamic obesity, BMI fell 16.5% against a 3.3% rise on placebo at 52 weeks. In POMC deficiency, 8 of 10 lost at least 10% of body weight in about a year.

Related on Grey Peptides

• Setmelanotide
• Melanotan II
• Melanotan II and PT-141

Sources

1. Ayers, K. L., et al. (2018). Melanocortin 4 Receptor Pathway Dysfunction in Obesity: Patient Stratification Aimed at MC4R Agonist Treatment. J Clin Endocrinol Metab, 103(7), 2601-2612. PMID: 29726959
2. Rhythm Pharmaceuticals. IMCIVREE (setmelanotide) US prescribing information: Indications and Usage with Limitations of Use, Warnings and Precautions 5.1-5.5, Adverse Reactions, Clinical Pharmacology 12.1 and 12.3. DailyMed version 14, effective April 1, 2026; read October 3, 2026.
3. Duckett, K., et al. (2026). Cross-species studies implicate the melanocortin 3 receptor more strongly in the control of pubertal development than energy balance. Mol Metab, 103, 102301. PMID: 41386534
4. Grey Peptides encyclopedia entries for setmelanotide (NDA 213793), melanotan II (unselective melanocortin agonist; not approved) and PT-141. Read October 3, 2026.
5. Clément, K., et al. (2020). Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol, 8(12), 960-970. PMID: 33137293
6. Haqq, A. M., et al. (2022). Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period. Lancet Diabetes Endocrinol, 10(12), 859-868. PMID: 36356613
7. Roth, C. L., et al. (2024). Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial. Lancet Diabetes Endocrinol, 12(6), 380-389. PMID: 38697184
8. Miller, J. L., et al. (2026). Setmelanotide for the Treatment of Acquired Hypothalamic Obesity. N Engl J Med, 395(2), 138-150. PMID: 42418774
9. Argente, J., et al. (2025). Setmelanotide in patients aged 2-5 years with rare MC4R pathway-associated obesity (VENTURE): a 1 year, open-label, multicenter, phase 3 trial. Lancet Diabetes Endocrinol, 13(1), 29-37. PMID: 39549719
10. VYLEESI (bremelanotide injection) US prescribing information, Warnings and Precautions 5.2 (focal hyperpigmentation). DailyMed version 1, effective November 13, 2025; read October 1, 2026.

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.